On this page
Molybdenum cofactor deficiency
This deficiency leads to severe neurological problems and other health issues, usually appearing in early infancy. It affects various body systems due to the impaired function of several important enzymes.
Available at Jeen Health
Clinical tests that include this
Overview
Molybdenum cofactor deficiency is a very rare, inherited metabolic condition. It occurs when the body cannot produce a crucial molecule called molybdenum cofactor. This cofactor is essential for the function of several enzymes that break down certain substances in the body, including sulphite, xanthine, and hypoxanthine [PMID:33678082]. Without a functional molybdenum cofactor, these enzymes cannot work correctly, leading to a build-up of toxic substances and a deficiency of important end-products.
The condition typically presents in newborns or young infants and can affect multiple organ systems, most notably the brain. The severity can vary, but it often leads to significant neurological impairment. Early diagnosis and management are important, as some forms of the condition may respond to treatment.
Symptoms & clinical features
Symptoms of molybdenum cofactor deficiency usually appear within the first days or weeks of life. Affected infants may present with severe and progressive neurological problems. These can include frequent seizures, which are often difficult to control, and significant feeding difficulties. Babies may also show signs of developmental delay, meaning they do not reach developmental milestones at the expected age.
Other clinical features can include low muscle tone (hypotonia) and an abnormally small head size (microcephaly), which may develop over time. The build-up of toxic substances like sulphite can cause brain damage, leading to the severe neurological symptoms observed in this condition [PMID:24657929]. Eye problems, such as dislocation of the lens, may also be observed in some individuals.
Video: Genetics 101
Affected organs
Molybdenum cofactor deficiency primarily affects the brain and nervous system, leading to profound neurological impairment. The lack of functional enzymes results in the accumulation of harmful substances that are toxic to brain cells. This can cause widespread damage to brain tissue, impacting its structure and function.
While the brain is most severely affected, other organs can also be impacted. The eyes can be affected, sometimes presenting with lens dislocation. The condition is a systemic metabolic disorder, meaning it affects processes throughout the body, but the most significant clinical manifestations are typically observed in the central nervous system.
Risks & severity
Molybdenum cofactor deficiency is generally a severe condition with significant health risks. The severity can vary depending on the specific genetic change, but it often leads to early-onset, progressive neurological deterioration. Most affected individuals experience severe developmental delay and intractable seizures [PMID:33678082]. The condition can be life-limiting, with many infants not surviving beyond early childhood.
The exact prevalence of molybdenum cofactor deficiency is not well established, but it is considered a very rare disorder worldwide. The age of onset is typically in the neonatal period or early infancy, with symptoms becoming apparent shortly after birth. The progressive nature of the neurological damage highlights the importance of early diagnosis and management where possible.
Genetic causes
Molybdenum cofactor deficiency is caused by pathogenic changes in specific genes responsible for producing the molybdenum cofactor. The genes currently known to be associated with this condition are GPHN, MOCS1, and MOCS2. The proteins encoded by these genes are all involved in different steps of the molybdenum cofactor biosynthesis pathway.
The MOCS1 gene directs the creation of proteins involved in the initial steps of molybdenum cofactor production. Similarly, MOCS2 codes for two proteins, MOCS2A and MOCS2B, which together form molybdopterin synthase, an enzyme critical for the synthesis of molybdenum cofactor. The GPHN gene encodes the gephyrin protein, which is essential both for creating molybdenum cofactor and for the proper function of nerve cells [PMID:24657929]. When these genes have pathogenic variants, the body cannot produce a functional molybdenum cofactor, leading to the symptoms of the deficiency.
- GPHN gephyrinThe GPHN gene provides instructions for the gephyrin protein, which is vital for synthesising molybdenum cofactor and plays a key role in neurotransmission within the brain.
- MOCS1 molybdenum cofactor synthesis 1The MOCS1 gene provides instructions for producing proteins crucial for the initial steps in the synthesis of molybdenum cofactor, a vital molecule for several enzyme functions in the body.
- MOCS2 molybdenum cofactor synthesis 2The MOCS2 gene provides instructions for creating two proteins essential for synthesising molybdenum cofactor, a vital molecule for several metabolic enzymes.
Inheritance pattern
Molybdenum cofactor deficiency is inherited in an autosomal recessive pattern. This means that an individual must inherit two altered copies of the same gene - one from each parent - to develop the condition.
Parents who each carry one altered copy of the gene are known as carriers. Carriers typically do not show any symptoms of the condition themselves. However, for each pregnancy, there is a 1 in 4 (25%) chance that their child will inherit two altered copies and be affected by molybdenum cofactor deficiency. There is also a 2 in 4 (50%) chance that the child will be a carrier, and a 1 in 4 (25%) chance that the child will inherit two working copies of the gene and not be affected, nor be a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of molybdenum cofactor deficiency often begins with clinical suspicion based on an infant's symptoms, particularly severe, early-onset seizures and developmental delay. Initial screening tests may include urine sulphite tests, which can detect the build-up of sulphite in the body. Blood tests may also show elevated levels of xanthine and hypoxanthine.
A definitive diagnosis is confirmed through genetic testing, which looks for pathogenic changes in the GPHN, MOCS1, or MOCS2 genes. This testing can be arranged through the NHS Genomic Medicine Service (GMS) by specialist clinicians, such as paediatric neurologists or metabolic specialists. The relevant R-code for Molybdenum cofactor deficiency is R159 Molybdenum cofactor deficiency. Genetic counsellors can provide support and information throughout the diagnostic process and help families understand the implications of a diagnosis.
Management & lifestyle
Management for molybdenum cofactor deficiency aims to alleviate symptoms and, in some cases, address the underlying metabolic defect. For some specific forms of the condition, particularly those caused by MOCS1 pathogenic variants, treatment with cyclic pyranopterin monophosphate (cPMP) may be beneficial. This compound can act as a substitute for the missing molybdenum cofactor, potentially improving outcomes if started very early [PMID:33678082].
Supportive care is crucial and includes managing seizures with anti-epileptic medications, providing nutritional support, and offering physiotherapy and occupational therapy to help with developmental delays. All care would be coordinated through specialist metabolic centres within the NHS, often involving multidisciplinary teams. Families are supported by clinical genetic services and genetic counsellors who can provide guidance on the condition and its inheritance.
UK care pathway
In the UK, individuals suspected of having rare genetic conditions like Molybdenum cofactor deficiency would typically be referred to a specialist metabolic service or paediatric neurology team within the NHS. These teams can initiate investigations, including genetic testing through the NHS Genomic Medicine Service (GMS).
Genetic testing for Molybdenum cofactor deficiency falls under NHS R-code R159. If a diagnosis is confirmed, ongoing care and management would be coordinated by a specialist team, often involving genetic counsellors. These professionals provide vital information and support to families, helping them understand the condition, its inheritance, and available care options.
Frequently asked questions
How common is Molybdenum cofactor deficiency?
Molybdenum cofactor deficiency is a very rare condition. The exact number of people affected is not precisely known, but it is considered to be one of the ultra-rare genetic disorders.
Can Molybdenum cofactor deficiency be treated?
For some specific types of Molybdenum cofactor deficiency, particularly those caused by changes in the MOCS1 gene, a treatment involving cyclic pyranopterin monophosphate (cPMP) can be beneficial if started early. Otherwise, management focuses on supportive care for symptoms like seizures.
If I am a carrier, what does that mean for my family?
If you are a carrier of a gene change for Molybdenum cofactor deficiency, it means you carry one altered copy of the gene but typically do not have symptoms. If your partner is also a carrier, there is a 25% chance in each pregnancy that your child could inherit two altered copies and be affected by the condition.
What kind of support is available for families affected by this condition?
Families affected by Molybdenum cofactor deficiency can receive support from specialist NHS metabolic teams, clinical genetic services, and genetic counsellors. These professionals offer information, guidance, and help with navigating care pathways and accessing relevant resources.
How is Molybdenum cofactor deficiency diagnosed in the UK?
Diagnosis in the UK typically involves initial clinical assessment and biochemical tests, followed by genetic testing through the NHS Genomic Medicine Service (GMS). This testing looks for specific changes in the GPHN, MOCS1, or MOCS2 genes.